OMI-DG1
Ovarian Cancer, Colorectal Cancer
PreclinicalActive
Key Facts
About Omideon
Omideon is a private, preclinical-stage biotech developing a new therapeutic modality centered on carbohydrate binding molecules (CBMs) to target cancer-specific glycans. Spun out from Pneumagen Limited, the company leverages a platform to engineer multivalent CBMs with high affinity for Tumor-Associated Carbohydrate Antigens (TACAs), aiming to disrupt multiple cancer-promoting pathways. Its lead asset, OMI-DG1, has shown in vivo proof-of-concept in ovarian cancer, and the company is seeking financing to advance it and expand into colorectal cancer. Omideon represents a novel approach in oncology by directly targeting the tumor glycome, an underexplored area with significant therapeutic potential.
View full company profile